Compare McKesson Corporation (MCK) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs ProShares UltraPro QQQ ETF — how do they compare? McKesson Corporation trades at $825.97 (market cap $97.35B), while ProShares UltraPro QQQ ETF trades at $70.17. The key difference: McKesson Corporation pays a 0.39% dividend while ProShares UltraPro QQQ ETF pays none, and ProShares UltraPro QQQ ETF is trading nearer its 52-week high, McKesson Corporation nearer its low. Which is the better fit depends on your goals.
| MCK | TQQQ | |
|---|---|---|
Market Cap | $97.35B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $995.69 | $87.22 |
52-Week Low | $659.01 | $37.89 |
Enterprise Value | $101.98B | — |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
TQQQ trades at $67.65, up 0.18% on the day, with a bearish technical signal driven by moving averages. The ETF faces structural costs and volatility risks, as highlighted in recent news. Key support lies at $66, with resistance at $69. Recent articles emphasize the amplified downside potential during market selloffs, questioning the long-term viability of leveraged strategies.
Outlook remains cautious due to high volatility and compounding costs. Opportunities exist for tactical traders during uptrends, but risks include severe drawdowns and daily rebalancing effects. Investors should weigh the 3x leverage against potential wealth destruction in downturns, as seen in 2022's 81% drop versus Nasdaq's 33% decline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
